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Abstract Uterine artery embolization (UAE) in patients
with a large ﬁbroid burden is controversial. Anecdotal
reports describe serious complications and limited clinical
results. We report the long-term clinical and magnetic
resonance (MR) results in a large series of women with a
dominant ﬁbroid of [10 cm and/or an uterine volume of
[700 cm
3. Seventy-one consecutive patients (mean age,
42.5 years; median, 40 years; range, 25–52 years) with a
large ﬁbroid burden were treated by UAE between August
2000 and April 2005. Volume reduction and infarction rate
of dominant ﬁbroid and uterus were assessed by comparing
the baseline and latest follow-up MRIs. Patients were
clinically followed at various time intervals after UAE with
standardized questionnaires. There were no serious com-
plications of UAE. During a mean follow-up of 48 months
(median, 59 months; range, 6–106 months), 10 of 71
patients (14%) had a hysterectomy. Mean volume reduc-
tion of the ﬁbroid and uterus was 44 and 43%. Mean
infarction rate of the ﬁbroid and overall ﬁbroid infarction
rate was 86 and 87%. In the vast majority of patients there
was a substantial improvement of symptoms. Clinical
results were similar in patients with a dominant ﬁbroid
[10 cm and in patients with large uterine volumes by
diffuse ﬁbroid disease. In conclusion, our results indicate
that the risk of serious complications after UAE in patients
with a large ﬁbroid burden is not increased. Moreover,
clinical long-term results are as good as in other patients
who are treated with UAE. Therefore, a large ﬁbroid bur-
den should not be considered a contraindication for UAE.
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Introduction
Uterine artery embolization (UAE) is an accepted alter-
native to surgery in the management of symptomatic
patients with uterine ﬁbroids [1–7]. However, the role of
UAE in symptomatic women with a large ﬁbroid burden is
subject to debate. In several small studies, response to
UAE was judged insufﬁcient in patients with a large
ﬁbroid, [8 cm, with a higher rate of need for additional
therapy after UAE [8, 9]. In addition, there is general
unspeciﬁed fear of an excessive effect after embolization
in these patients due to rapid ischemia and necrosis. This
fear is based on several early case reports describing rare
but serious complications shortly after UAE for large ﬁb-
roids, such as unbearable pain, infection, septic uterine
necrosis, and lethal sepsis [10–12]. On the other hand,
some studies suggest that results of UAE in patients with a
large ﬁbroid burden are as good as in other patients with
symptomatic ﬁbroids, with comparable low rates of serious
complications [13–15]. However, long-term follow-up
studies in this special subset of patients have not been
performed to date.
In this study, we retrospectively evaluated the long-term
results of UAE in symptomatic women with a large ﬁbroid
burden.
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Patients
This retrospective study was approved by the Institutional
Review Board, with a waiver for informed consent. From
an institutional database with prospectively collected data
on 431 women with symptomatic uterine ﬁbroids treated
with UAE between August 2000 and April 2005, 71 con-
secutive women were selected with a large ﬁbroid burden,
deﬁned as a dominant ﬁbroid with a longest axis[10 cm
and/or a uterine volume of[700 cm
3. Diagnosis of uterine
ﬁbroid disease was established by history, clinical gyne-
cological examination, and magnetic resonance (MR)
imaging (MRI). All women had previous medical therapies
for their complaints without sufﬁcient clinical results.
Exclusion criteria for UAE were pregnancy, pelvic
inﬂammatory disease, gynecological malignancy, pure
adenomyosis, and thin-stemmed pedunculated ﬁbroids.
All 71 women were premenopausal, with a mean age of
42.5 years (median, 40 years; range, 25–52 years). Pre-
senting symptoms of 71 women were bleeding in 60 (85%),
pain in 41 (58%), and bulk-related symptoms in 64 (90%).
Of 71 women, 42 (59%) had a ﬁbroid[10 cm, and 30 of
these 42 women had an overall uterus volume of
[700 cm
3. The remaining 29 women (41%) had a uterus
volume of[700 cm
3 but no ﬁbroid larger than 10 cm.
Patients were categorized into three subgroups: group A,
patients with a dominant ﬁbroid diameter of[10 cm and a
uterine volume of \700 cm
3 ([10 cm, \700 cm
3); group
B, patients with a dominant ﬁbroid of [10 cm and an
uterine volume of [700 cm
3 ([10 cm, [700 cm
3); and
group C, patients with a uterine volume of[700 cm
3 and
with ﬁbroids smaller than 10 cm (\10 cm, [700 cm
3).
Presenting symptoms of the subgroups of patients are
reported in Table 1.
MRI at Baseline and Follow-up
All patients had native and contrast-enhanced MRI prior to
embolization and at various intervals postembolization.
From baseline MRI, the dimensions and volumes of the
ﬁbroids and uterus were assessed. Volume calculation was
done using the formula of a prolate ellipse (length 9 -
depth 9 width 9 0.5233). Dominant ﬁbroid infarction rate
and overall ﬁbroid infarction rate after UAE were assessed
by two observers in consensus on the latest MRI by visual
estimation of a decrease in enhancement compared to the
baseline MRI as described by Siskin [16]. Infarction of
\80% was considered insufﬁcient.
Embolization Procedure
UAE was performed after selective catheterization of both
uterine arteries via a unilateral approach. The use of a
microcatheter was left to the discretion of the physician. In
women who desired future pregnancy, embolization was
performed simultaneously on both sides to limit radiation
exposure. Various embolic agents (Contour SE, Embo-
Gold, Bead Block, and Embosphere Microspheres) ranging
in size from 500 to 900 lm were used. The end point was
complete occlusion of arteries to the periﬁbroid plexus,
with sluggish ﬂow in the ascending segment of the uterine
artery, leaving the main uterine artery, cervico-vaginal
branches, and uteroovarian anastomoses patent [17].
Complications were recorded.
Clinical Follow-up
Baseline clinical status was assessed by an interview using
a standardized questionnaire on patient’s symptoms of
bleeding, pain, and bulk. At various time intervals after
UAE patients returned for a follow-up MRI and an inter-
view by a nurse practitioner to assess the evolution of
symptoms using the same questionnaire. For the purposes
of this study, in July 2009 all women were requested to ﬁll
out the validated Uterine Fibroid Symptom and Quality of
Life questionnaire (UFS-QOL) [18]. In addition, women
were asked to ﬁll out the standardized questionnaire,
aiming at the long-term evolution of their baseline symp-
toms, additional therapy, and adverse events such as vag-
inal dryness and discharge, menopausal complaints, or
ﬁbroid expulsion. In women who did not return the ques-
tionnaire of July 2009, data of the latest previously avail-
able follow-up interval were considered the ﬁnal result.
Data Analysis
Complications are expressed as a proportion. The ﬁbroid
diameter change during follow-up and the rate of uterine
volume reduction were assessed for all patients and the
three subgroups by comparison of the latest MRI with
baseline. Volume reduction of large ﬁbroid and uterus was
calculated as a proportion of the initial volume. Differences
in volume reduction of dominant ﬁbroid and uterus and
Table 1 Presenting symptoms of 71 patients with a large ﬁbroid
burden in three subgroups
Group Bleeding Pain Bulk-related
symptoms
A( N = 12):[10 cm,\700 cm
3 96 1 1
B( N = 30):[10 cm,[700 cm
3 25 16 26
C( N = 29):\10 cm,[700 cm
3 26 19 27
All (N = 71) 60 41 64
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123differences in infarction rates were evaluated among the
three subgroups. Chi-square test or Fisher’s exact test was
used for comparison of proportions, and t-test for com-
parison of means. p-Values\0.05 were considered sig-
niﬁcant. Statistical analysis was done with MedCalc
statistical software (MedCalc, Mariakerke, Belgium).
Results
Imaging Results
Mean MRI follow-up was 13.8 months (median,
12 months; range, 4–47 months). The dominant ﬁbroid
diameter and volume reduction, uterine volume reduction,
and infarction rates of the dominant ﬁbroid and overall
ﬁbroid infarction rate for all patients and the three sub-
groups are reported in Table 2, and a representative image
is shown in Fig. 1. After UAE, mean infarction rates of
both the dominant ﬁbroid and the overall ﬁbroid infarction
rate were high (85–90%) in all three subgroups. On an
individual basis, in 20 of 71 patients (28%) the infarction
rate was considered insufﬁcient, at\80%. One patient had
recurrent symptoms without additional therapy, and eight
patients had good clinical results despite the insufﬁcient
infarction rate. The remaining 11 patients had additional
therapy during follow-up.
Adverse Events
Adverse events were reported by 21 patients (29.5%).
Transient amenorrhea occurred in ﬁve women, and per-
manent amenorrhea in another ﬁve (one 43-year-old
woman and four women older than 47 years). One woman
reported a ﬁbroid expulsion 2 months after UAE, three
reported ﬁbroid sloughing, and two had vaginal discharge.
Three women needed additional pain medication. Three
women developed an unspeciﬁed urogenital infection,
successfully treated with antibiotics. None of the patients
developed severe postembolic syndrome. There was no
emergency surgery after UAE.
Additional Therapy During the Follow-up
During a mean follow-up of 48 months (median,
59 months; range, 6–106 months), 18 of 71 patients (25%)
underwent additional therapy. The distribution of patients
with additional therapy in the three subgroups is reported
in Table 3. Eight women had a second embolization. In six
of eight women ﬁbroids were initially completely devas-
cularized but showed revascularization on later MRI. In the
other two women the ﬁbroids were initially not completely
devascularized due to additional vascular supply from the
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123ovarian artery and the inferior mesenteric artery (Fig. 2);
this was corrected in the repeat embolization. After repeat
UAE all ﬁbroids remained devascularized on subsequent
MRI.
Ten women had a hysterectomy due to insufﬁcient relief
of clinical symptoms. In one patient, with fever and vaginal
discharge, a hysterectomy was performed early, at 7 weeks
after UAE. Pathological examination showed normal
uterine stroma, without signs of necrosis. In one patient
hysterectomy was performed after recurrence of symptoms
4 years after UAE.
Evolution of Presenting Symptoms
The late follow-up questionnaire in July 2009 was returned
by 44 of 71 patients (62%) and these patients had a mean
follow-up duration of 68 months (median, 73 months;
range, 48–106 months). Of these 44 patients, 13 had
additional therapies and were censored from ﬁnal follow-
up. The long-term evolution of symptoms in the remaining
31 patients is reported in Table 4. The second part of the
questionnaire, the UFS-QOL was ﬁlled out by 35 of the 44
patients: 7 patients had a hysterectomy, 1 a second
embolization, and 1 patient was menopausal at the age of
54, 6 years after UAE. Results are reported in Table 5.
After UAE the symptom severity score and the health-
related quality-of-life (HRQL) total score of our patient
group are within the range of normal women; scores for the
other subscales are in the range of mildly symptomatic
patients.
Of the 71 patients, 27 patients did not return the long-
term questionnaire and had a shorter mean follow-up, of
14 months (median, 12 months; range, 6–40 months). In 5
Fig. 1 Sagittal contrast-
enhanced MRI in a 31-year
woman. After embolization, the
ﬁbroid is completely infarcted
with a volume reduction of 60%
Table 3 Additional therapy after uterine artery embolization (UAE)
during mean follow-up of 48 months in 71 patients with a large
ﬁbroid burden and in the three subgroups
Group Additional
UAE
Hysterectomy Total
A( N = 12):[10 cm,
\700 cm
3
1 2 3 (25%)
B( N = 30):[10 cm,
[700 cm
3
4 5 9 (30%)
C( N = 29):\10 cm,
[700 cm
3
3 3 6 (21%)
All (N = 71) 8 10 18 (25%)
Fig. 2 Angiogram 14 months after insufﬁcient result of ﬁrst emboli-
zationina44-year-oldwomanwithalargeﬁbroidburdendemonstrates
a substantial additional vascular supply to the uterus from the inferior
mesenteric artery, not appreciated at ﬁrst embolization
946 A. J. Smeets et al.: Uterine Artery Embolization in Patients with a Large Fibroid Burden
123of 27 patients additional therapies were performed. Evo-
lution of symptoms of the remaining 22 women is reported
in Table 6.
Data Analysis
Statistical evaluation of the differences in dominant ﬁbroid
volume reduction, uterine volume reduction, and infarction
rates among the three subgroups did not show signiﬁcant
results.
Discussion
UAE is, at present, gaining acceptance as an alternative to
hysterectomy or myomectomy in symptomatic women
with uterine ﬁbroids. Many women appreciate the results
that can be obtained with UAE: improvement or elimina-
tion of symptoms and reduction of uterine size, with
maintenance of the uterus and preservation of fertility. In
many studies the good long-term results and low compli-
cation rates of this treatment have been reported [5–7].
Despite these overall satisfying results, in the subgroup of
patients with a large ﬁbroid burden, a higher rate of serious
ischemic, necrotic, and infectious complications is ascri-
bed, based on several anecdotal reports [9–11].
Our results show that a large ﬁbroid burden does not
decrease the efﬁcacy of UAE and there is no higher com-
plication rate. Our results in patients with a large ﬁbroid
burden are comparable and in the same range as in large
studies reporting on results of UAE in unselected patients
[6, 7]. In the vast majority of our patients there is a sig-
niﬁcant volume reduction of the ﬁbroids in combination
with good clinical results.
The rate of adverse events after UAE in patients with a
large ﬁbroid burden was very low, and emergent surgery
was never necessary. These results are valid for patients
with a very large dominant ﬁbroid, as well as for patients
with a large uterine volume from many smaller ﬁbroids or
the combination. During long-term follow-up, the fre-
quency of additional embolization and hysterectomy in our
selected patients was in the same range as in previous
studies on unselected patients [6]. Our ﬁndings suggest
that, in women with a large ﬁbroid burden who are reluc-
tant to undergo hysterectomy, UAE is a valuable alterna-
tive with a high rate of success in preserving the uterus.
Table 4 Long-term clinical
follow-up results after a mean of
68 months in 31 patients treated
with uterine artery embolization
for a large ﬁbroid burden who
returned the late questionnaire
and had no additional therapy
Group Bleeding
(no. improved)
Pain
(no. improved)
Bulk-related symptoms
(no. improved)
A( N = 6):[10 cm,\700 cm
3 4o f4 3o f3 6o f6
B( N = 13):[10 cm,[700 cm
3 11 of 11 6 of 6 13 of 13
C( N = 12):\10 cm,[700 cm
3 4o f4 3o f3 6o f6
All (N = 31) 19 of 19 12 of 12 25 of 25
Table 5 Uterine Fibroid Symptom and Quality of Life questionnaire after a mean of 68 months in 35 patients treated with uterine artery
embolization for a large ﬁbroid burden who returned the late questionnaire and had no additional therapy
Group Symptom
severity
Concern Activities Energy
mood
Control Self-
conscious
Sexual
function
HRQL total
A( N = 7):[10 cm,\700 cm
3 17.4 78.6 75 69.9 72.9 78.6 58.9 86.6
B( N = 16):[10 cm,[700 cm
3 12.1 62.6 66.9 84.8 66.3 59.5 65 84.6
C( N = 12):\10 cm,[700 cm
3 22.5 87.3 94.2 95.8 94.1 91.7 81.8 92.5
All (N = 35) 16.6 72.1 75.4 82.8 74.7 72.1 67.3 87.7
Table 6 Clinical follow-up after a mean of 14 months in 22 patients treated with uterine artery embolization for a large ﬁbroid burden who did
not return the late questionnaire and had no additional therapy
Group Bleeding Pain Bulk-related
symptoms
A( N = 3):[10 cm,\700 cm
3 3 of 3 improved 1 of 1 improved 2 of 2 improved
B( N = 8):[10 cm,[700 cm
3 5 of 6 improved 1 of 3 improved 5 of 6 improved
1 of 6 unchanged 2 of 3 unchanged 1 of 6 unchanged
C( N = 11):\10 cm,[700 cm
3 7 of 8 improved 9 of 10 improved 8 of 10 improved
1 of 8 unchanged 1 of 10 unchanged 2 of 10 unchanged
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123Our study has several limitations. Long-term clinical
follow-up was not available for all patients. The UFS-QOL
was assessed only at long-term follow-up, and not at
baseline. However, strong points of our study were the
follow-up duration of more than 5 years in the majority of
patients and the complete clinical follow-up in terms of
additional treatments.
Our study is the ﬁrst on UAE in patients with a large
ﬁbroid burden in a large patient group and with long-term
follow-up. Several studies on limited patient groups and
with a shorter follow-up have reported good results similar
to ours [13, 14].
Some authors consider a large ﬁbroid burden a risk
factor for serious complications such as infections and
ischemic uterine injury requiring emergent hysterectomy,
and it is advocated that UAE should not be performed for
multiple ﬁbroids [10 cm in diameter or a large uterine
volume. However, the presumption to refrain from UAE in
these patients is based on a few early case reports
describing serious complications [9, 11]. Katsumori was
the ﬁrst to report on results of UAE in 47 patients with
large ﬁbroids as part of a cohort of 152 patients with a
mean follow-up of 17 months [19]. The conclusion of that
study was that there was no increased risk to patients
undergoing UAE for ﬁbroids on the basis of size. Later,
these good results were conﬁrmed in a smaller study with
the limited follow-up of 12 months [13].
In conclusion, our results conﬁrm previous reports that
the risk of serious complications after UAE in patients with
large ﬁbroids is not increased. Moreover, clinical long-term
results are as good as in other patients with symptomatic
ﬁbroids treated with UAE. Therefore, a large ﬁbroid burden
should not be considered a contraindication for UAE.
Open Access This article is distributed under the terms of the
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